{
    "relation": [
        [
            "",
            "ABC/3TC FDC",
            "TDF/FTC FDC"
        ],
        [
            "Description",
            "Abacavir (ABC) 600 mg/lamivudine (3TC) 300 mg fixed dose combination (FDC) once daily (QD) plus 600 mg efavirenz QD",
            "Tenofovir (TDF) 300 mg/emtricitabine (FTC) 200 mg FDC once daily (QD) plus 600 mg efavirenz QD"
        ]
    ],
    "pageTitle": "KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00549198?sect=Xj0156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988312.76/warc/CC-MAIN-20150728002308-00081-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 871151155,
    "recordOffset": 871135759,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Abacavir/lamivudine and efavirenz Drug: Tenofovir/Emtricitabine and efavirenz Interventions: Infection, Human Immunodeficiency Virus I HIV Infection Conditions: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: September 23, 2010 \u00a0",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 ABC/3TC FDC \u00a0 \u00a0 TDF/FTC FDC \u00a0 STARTED \u00a0 \u00a0 195 [1] \u00a0 197 [2] COMPLETED \u00a0 \u00a0 115 \u00a0 \u00a0 134 \u00a0 NOT COMPLETED \u00a0 \u00a0 80 \u00a0 \u00a0 63 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 28 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 26 \u00a0 Insufficient Viral Load Response \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 4 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 Protocol-defined Virological Failure \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 7 \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}